Evidence map›Paper›PMID 35805147›Full record

ArticleCells2022

Differences in Antioxidant and Lipid Handling Protein Expression Influence How Cells Expressing Distinct Mutant TP53 Subtypes Maintain Iron Homeostasis.

Cameron J Cardona, Evan R Hermann, Kate N Kouplen, Steven D Hartson, McKale R Montgomery

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Cameron J CardonaDepartment of Nutritional Sciences, Oklahoma State University, Stillwater, OK 74078, USA.ORCID 0000-0001-6633-2022
Evan R HermannDepartment of Nutritional Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
Kate N KouplenDepartment of Integrative Biology, Oklahoma State University, Stillwater, OK 74078, USA.ORCID 0000-0002-4244-3470
Steven D HartsonBiochemistry and Molecular Biology, Oklahoma State University, Stillwater, OK 74078, USA.
McKale R MontgomeryDepartment of Nutritional Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
Oklahoma State University · US

Funding

Proteomics CoreU54DK110858 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Anna E Beaudin, JAMES Eric COX · 2016 to 2026
$8.6M
Impact of P53 Mutations on Cancer Cell Iron MetabolismR03CA241876 · NCI · OKLAHOMA STATE UNIVERSITY STILLWATER · PI MONTGOMERY, MCKALE · 2020 to 2020
$145k
NCI NIH HHS R03 CA241876NCI NIH HHS R03CA259595NIDDK NIH HHS U54 DK110858NIDDK NIH HHS U54DK110858
6 · The paper itself

Abstract

The tumor suppressor TP53 is the most commonly mutated gene in human cancers, and iron is necessary for cancer cell growth and proliferation, but there is a significant gap in knowledge for how the two cooperate to affect cellular physiology. Elucidating this role is complicated, however, because each TP53 mutation subtype exhibits unique phenotypic responses to changes in iron availability. The goal of this work was to determine how cells expressing distinct TP53 mutation subtypes respond to iron restriction. Utilizing a reverse genetics approach, we generated eight isogenic cell lines that either lacked TP53 expression, expressed wild-type TP53, or expressed one of the six most common TP53 "hotspot" mutations. We then employed isobaric peptide labeling and mass spectrometry to quantitively measure changes in global protein expression, both in response to induction of mutant TP53 expression, and in response to iron chelation. Our findings indicate that mutant TP53-dependent sensitivities to iron restriction are not driven by differences in responsiveness to iron chelation, but more so by mutant TP53-dependent differences in cellular antioxidant and lipid handling protein expression. These findings reinforce the importance of distinguishing between TP53 mutation subtypes when investigating approaches to target mutant TP53. We also identify unique TP53-dependent perturbances in protein expression patterns that could be exploited to improve iron-targeted chemotherapeutic strategies.

Indexed as

AntioxidantsTumor Suppressor Protein p53HomeostasisHumansIronIron Chelating AgentsLipidsAntioxidantsIronIron Chelating AgentsLipidsTP53 protein, humanTumor Suppressor Protein p53cancerferroptosisiron metabolismmutant TP53proteomics

Identifiers

PMID35805147
PMCPMC9265551
OpenAlexW4283736137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.